维普期刊资源整合服务平台（V6.5）

21篇 您的检索式：作者名="Calcagno D"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Vascular endothelial growth factor stimulates organ2specific host mat rix metalloproteinase-9 expression and ovarian cancer invasion显示文摘	Belotti D Calcagno C Garofalo A	2008	Mol Cancer Res2008，6，4：	1
2	Clinical response to Thalidomide and colchicine in two siblings with Behcet’s disease carrying a single mutated MEFV allele显示文摘	Rigante D La Torre F Calcagno G A	2012	Rheumatol Int2012，32，6：	1
3	Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics显示文摘	Calcagno A M Salcido C D Gillet J P	2010	J Natl Cancer Inst2010，102，21：	1
4	Brcal breast tumours contain distinct CD44+/CD24 and CD133^+ cells with cancer stem cell characteristics显示文摘	Wright M H Calcagno A M Salcido C D	2008	Breast Cancer Res2008，10，：	1
5	Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics显示文摘	Wright M H Calcagno A M Salcido C D	2008	Breast Cancer Res2008，10，1：	1
6	Clinical response to thalidomide and colchicine in two siblings with Behcet's disease carrying a single mutated MEFV allele显示文摘	Rigante D La Torre F Calcagno G	2012	Rheumatol Int2012，32，6：	1
7	Abdominal aortic aneurysm surgery: the basic evaluation of cardiac risk显示文摘	Perry MO Calcagno D	1998	Ann Surg1998，208，7：	1
8	Breal breast tumors eontain distinct CD44^+/CD24 and CD133^+ eells with eaneer stem cell characteristics显示文摘	Wright M H Calcagno A M Saleido C D	2008	Breast Cancer Res2008，10，1：	1
9	High-fat feeding stimulates endocrine, glucose-dependent insalinotropie polypeptide (GIP)- expressing cell hyperplasia in the duodenum of Wistar rats 显示文摘	Gniuli D Calcagno A Dalla L	2010	Diabetologia2010，53，10：	1
10	Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism 显示文摘	D'Alessandro G Calcagno E Tartari S	2011	Neurobiol Dis2011，43，2：	1
11	Semiautomatic permeance tester for thick magnetic films显示文摘	Calcagno P A Thompson D A	1975	Rev Sci Instrurn1975，46，：	1
12	Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics显示文摘	Wright M H Calcagno A M Salcido C D	2008	Breast Cancer Res2008，10，1：	1
13	Brcalbreast tumors contain distinct CD44 + /CD24 - andCD133 + cells with cancer stem cell characteristics 显示文摘	Wright M H Calcagno A M Salcido C D al	2008	Breast Cancer Res2008，10，1：	1
14	Aortic pseudoaneurysm from aortic penetration with a bird's nest vena cava filter显示文摘	Campbell JJ Calcagno D		0，，03：	1
15	Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion显示文摘	Belotti D Calcagno C Garofalo A	2008	Mol Cancer Res2008，6，4：	1
16	Vascular endothelial growth factor stimulates organ-specific host matrix metallopro- teinase-9 expression and ovarian cancer invasion 显示文摘	Belotti D Calcagno C Garofalo A	2008	Mol Cancer Res2008，6，4：	1
17	High plant diversity is needed to maintain ecosystem services显示文摘	Isbell F Calcagno V Hector A Connolly J Harpole WS Reich PB Scherer-Lorenzen M Schmid B Tilman D van Ruijven J Weigelt A Wilsey B J Zavaleta ES Loreau M		0，，：	1
18	Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics显示文摘	Wright M H Calcagno A M Salcido C D	2008	Breast Cancer Res2008，10，1：	1
19	Effects of High-fat Diet Exposure During Fetal Life on Type 2 Diabetes Development in the Progeny显示文摘	Gniuli D Calcagno A Caristo ME	2008	J Lipid Res2008，49，9：	1
20	FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study显示文摘BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(aPDAC).FOLFOXIRI,a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil,has demonstrated efficacy and feasibility in colorectal cancer.AIM To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.METHODS Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions,with either FOLFOXIRI(n=165)or FOLFIRINOX(n=124)regimens.FOLFOXIRI consisted of irinotecan(165 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2)and 5-fluorouracil(3200 mg/m2 as a 48-h continuous infusion)every 2 wk.Ninety-six pairs of patients were selected through propensity score matching,and clinical outcomes of the two treatment regimens were compared.RESULTS Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts,respectively.After propensity score matching,survival rates remained similar between the two regimens in terms of overall survival(hazard ratio=1.22;P=0.219)and progression-free survival(hazard ratio=1.27;P=0.120).The objective response rate was 37.1%in the FOLFOXIRI group vs 47.8%in the FOLFIRINOX group(P=0.187).Grade 3/4 toxicities occurred in 28.7%of patients in the FOLFOXIRI cohort vs 19.5%in the FOLFIRINOX cohort(P=0.079).FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse events.Hematopoietic growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5%with both regimens.CONCLUSION FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX.The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors.	Angélique Vienot Hortense Chevalier Clément Bolognini Elisabeta Gherga Elodie Klajer Aurélia Meurisse Marine Jary Stefano Kim Christelle d’Engremont Thierry Nguyen Fabien Calcagno Hamadi Almotlak Francine Fein Meher Nasri Syrine Abdeljaoued Anthony Turpin Christophe Borg Dewi Vernerey	2020	World Journal of Gastrointestinal Oncology2020，12，3：	0

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示